Abstract
The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.
| Original language | English |
|---|---|
| Pages (from-to) | 130-132 |
| Number of pages | 3 |
| Journal | Acta Neurologica Scandinavica |
| Volume | 90 |
| Issue number | 2 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. / Pisani, F.; Fazio, A.; Oteri, G.; Artesi, C.; Xiao, B.; Perucca, E.; Di Perri, R.
In: Acta Neurologica Scandinavica, Vol. 90, No. 2, 1994, p. 130-132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy
AU - Pisani, F.
AU - Fazio, A.
AU - Oteri, G.
AU - Artesi, C.
AU - Xiao, B.
AU - Perucca, E.
AU - Di Perri, R.
PY - 1994
Y1 - 1994
N2 - The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.
AB - The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.
UR - http://www.scopus.com/inward/record.url?scp=0027930972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027930972&partnerID=8YFLogxK
M3 - Article
C2 - 7801739
AN - SCOPUS:0027930972
VL - 90
SP - 130
EP - 132
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
SN - 0001-6314
IS - 2
ER -